Loading...
XCSE
PEG
Market cap15mUSD
Jul 09, Last price  
0.08DKK
1D
3.79%
1Q
-2.61%
IPO
-79.95%
Name

Pharma Equity Group A/S

Chart & Performance

D1W1MN
XCSE:PEG chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
107.62%
Rev. gr., 5y
%
Revenues
0k
00517,00015,486,00013,252,00049,367,000132,000620,0001,054,000000000000
Net income
-25m
L+3.93%
-92,669,000-12,036,000-1,415,000-16,978,000-43,279,000-141,827,000-5,930,000-2,773,000-1,035,000177,000-7,713,000-14,417,000-32,875,0005,392,0003,479,000-24,609,000-24,422,000-25,382,000
CFO
-18m
L-22.75%
0-744,000-17,747,000-5,713,000-10,559,000-5,789,000-4,800,000-2,938,000-181,000-4,921,000-1,579,000-274,000-9,905,000-2,089,000-2,874,000-16,624,000-22,861,000-17,661,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Operating from Hørsholm, Denmark, Pharma Equity Group A/S is an investment firm primarily focused on the life sciences industry. The company strategically provides early-stage capital to ventures that are developing advanced technologies and treatments designed to improve human health and elevate the quality of life.
URL
https://pharmaequitygroup.com/
IPO date
Jun 25, 2003
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT